Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Bibliographic Details
Main Authors:	Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2024-04-01
Series:	Clinical and Molecular Hepatology
Subjects:	masld biomarkers multiomics clinical relevance
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-0136.pdf

Similar Items

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
by: Sumin Oh, et al.
Published: (2024-04-01)

Refining the Role of EGR1 as a Biomarker in MASLD [Letter]
by: Zeng X
Published: (2025-02-01)

Updated mechanisms of MASLD pathogenesis
by: Yuxuan Li, et al.
Published: (2024-04-01)

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
by: Ziyan Pan, et al.
Published: (2024-09-01)

Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
by: Su Bin Lim, et al.
Published: (2024-10-01)

Innate Immunity and MASLD
by: Moritz Meyer, et al.
Published: (2024-04-01)

The LIDPAD Mouse Model Captures the Multisystem Interactions and Extrahepatic Complications in MASLD
by: Zun Siong Low, et al.
Published: (2024-09-01)

From MASLD to HCC: What's in the middle?
by: Alessia Provera, et al.
Published: (2024-08-01)

Dietary pattern modifies the risk of MASLD through metabolomic signature
by: Hanzhang Wu, et al.
Published: (2024-08-01)

Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents
by: Guang-Xia Shi, et al.
Published: (2024-10-01)

Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
by: Allison Soto, et al.
Published: (2024-02-01)

Research progress on AMPK in the pathogenesis and treatment of MASLD
by: Jiang Feng, et al.
Published: (2025-03-01)

Research advances in the diagnosis and treatment of MASLD/MASH
by: Dekai Wang, et al.
Published: (2025-12-01)

From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status
by: Andrea Boccatonda, et al.
Published: (2024-10-01)

Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
by: Haoxuan Zou, et al.
Published: (2024-07-01)

Environment, Endocrine Disruptors, and Fatty Liver Disease Associated with Metabolic Dysfunction (MASLD)
by: Antonella Mosca, et al.
Published: (2024-01-01)

Exploratory Role of Flavonoids on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a South Italian Cohort
by: Caterina Bonfiglio, et al.
Published: (2024-10-01)

Green Tea Polyphenol (-)-Epicatechin Pretreatment Mitigates Hepatic Steatosis in an In Vitro MASLD Model
by: Marija Hefer, et al.
Published: (2024-08-01)

Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
by: Salvatore Pezzino, et al.
Published: (2024-01-01)

Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
by: Apichat Kaewdech, et al.
Published: (2024-04-01)

Searching for novel cellular targets for MASLD and HCC within the humble lysosomal cathepsins
by: Alejandro del Castillo-Cruz, et al.
Published: (2024-09-01)

The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review
by: Maria Martin-Grau, et al.
Published: (2024-06-01)

Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Majid Mufaqam Syed-Abdul
Published: (2023-12-01)

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
by: David Pérez Compte, et al.
Published: (2024-04-01)

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
by: Eileen Laurel Yoon, et al.
Published: (2024-10-01)

Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives
by: Torre E, et al.
Published: (2024-10-01)

Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin
by: Marica Meroni, et al.
Published: (2024-05-01)

MASLD treatment—a shift in the paradigm is imminent
by: Mariana Verdelho Machado, et al.
Published: (2023-12-01)

Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study
by: Chengcheng Tong, et al.
Published: (2024-11-01)

Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota
by: Lu Dong, et al.
Published: (2025-03-01)

Liver Elastography for Liver Fibrosis Stratification: A Comparison of Three Techniques in a Biopsy-Controlled MASLD Cohort
by: Antonio Liguori, et al.
Published: (2025-01-01)

Association of triglyceride-glucose related indices with mortality among individuals with MASLD combined with prediabetes or diabetes
by: Yiheng Zhang, et al.
Published: (2025-02-01)

New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
by: Marija Branković, et al.
Published: (2024-01-01)

BMI gain and dietary characteristics are risk factors of MASLD in non-obese individuals
by: Hirokazu Taniguchi, et al.
Published: (2025-01-01)

Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis
by: Adrian Rotaru, et al.
Published: (2025-02-01)

Potential predictive role of Non-HDL to HDL Cholesterol Ratio (NHHR) in MASLD: focus on obese and type 2 diabetic populations
by: Xiao-Man Ma, et al.
Published: (2025-02-01)

The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
by: Qiong Lv, et al.
Published: (2024-12-01)

Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Sara Jarmakiewicz-Czaja, et al.
Published: (2025-01-01)

The combined pioglitazone and topiramate therapy for management of pediatric patients with severe MASLD
by: Callen Conroy, et al.
Published: (2024-08-01)

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
by: Tatjana Radosavljevic, et al.
Published: (2024-07-01)